The HERACLES diagnostic criteria utilized for colorectal cancer (all tumors expressing 3+ HER2 score in >50% of cells using immunohistochemistry or expressing 2+ HER2 score with a HER2:CEP17 ratio >2 in >50% of cells using FISH) were used to select patients for trial enrollment in three studies including Fu et al., Bianchi et al. and Tosi et al. [30,31,33]. Here, ERBB2 is linked to colorectal cancer.